BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:7 Hills Pharma\, LLC readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies 7 Hills Pharma\, LLC's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06362369-2340@assetmemo.bio
DTSTAMP:20261121T010129Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alintegimod: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Alintegimod\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followe
 d by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/alintegimod#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/alintegimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
